Mayo Clinic SPORE in Pancreatic Cancer
NCI grant awarded: September 2014
Amount: $11.3 million over five years
Principal investigator: Gloria M. Petersen, Ph.D.
The Mayo Clinic Cancer Center is one of three cancer centers in the U.S. to receive a Specialized Program of Research Excellence (SPORE) grant for pancreatic cancer from the National Cancer Institute (NCI).
The Mayo Clinic SPORE in Pancreatic Cancer is specifically committed to reducing the incidence and mortality of pancreatic cancer. The SPORE promotes research focused on understanding the causes of pancreatic cancer and the pathways by which the disease progresses.
Patients with cancers of the pancreas generally have a poor prognosis, with a five-year survival rate of about only 7 percent. According to the National Cancer Institute, pancreatic cancer is the fourth-leading cause of cancer death in the United States and accounts for more than 40,000 deaths annually.
The Mayo Clinic SPORE in Pancreatic Cancer has four translational research projects, focusing on cutting-edge approaches to early detection and treatment of pancreatic cancer. The SPORE has four cores supporting its research. And broad institutional support throughout Mayo Clinic helps pave the way for the translation of scientific discoveries to help patients with pancreatic cancer and those at risk of pancreatic cancer.
The SPORE also nurtures innovative research and interdisciplinary interactions, which attracts scientists and clinicians dedicated to pancreatic cancer research.
Several innovative translational pilot projects are awarded annually through the SPORE's Developmental Research Program, with matching funds from Mayo Clinic. The SPORE's Career Development Program supports one junior faculty member each year.
For more information about the Mayo Clinic SPORE in Pancreatic Cancer, see: